Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors.
Sharma
A
A
Mani
S
S
Hanna
N
N
Guha
C
C
Vikram
B
B
Weichselbaum
R R
RR
Sparano
J
J
Sood
B
B
Lee
D
D
Regine
W
W
Muhodin
M
M
Valentino
J
J
Herman
J
J
Desimone
P
P
Arnold
S
S
Carrico
J
J
Rockich
A K
AK
Warner-Carpenter
J
J
Barton-Baxter
M
M
D016907:Adverse Drug Reaction Reporting Systems / Q000592:standards; D002985:Clinical Protocols / Q000592:standards; D017321:Clinical Trials, Phase I as Topic / Q000331:legislation & jurisprudence / Q000379:methods / Q000592:standards; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D018014:Gene Transfer Techniques; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis / Q000188:drug therapy* / Q000532:radiotherapy*; D009369:Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D018579:Patient Selection; D014409:Tumor Necrosis Factor-alpha / Q000008:administration & dosage* / Q000009:adverse effects / Q000235:genetics / Q000627:therapeutic use*
D014409:Tumor Necrosis Factor-alpha